Wall Street Bullish on ​Precigen (PGEN) As the Company Transitions to Commercial Stage

​Wall Street is bullish connected Precigen, Inc. (NASDAQ:PGEN) aft the institution posted encouraging fiscal Q4 2025 net connected March 25. Following the merchandise connected April 2, H.C. Wainwright reiterated a Buy standing connected the banal with a $10 terms target. Earlier connected March 26, Citizen JMP had raised the terms people connected the banal from $8 to $9, portion reiterating a Buy standing connected the shares.

​Precigen, Inc. (NASDAQ:PGEN) transitioned from a objective to commercialized signifier institution successful August 2025 with the FDA support for PAPZIMEOS to dainty adults with recurrent respiratory papillomatosis (RRP). During the fiscal 4th fourth of 2025, PAPZIMEOS generated $3.4 cardinal successful nett income and marked the archetypal partial 4th of US commercialized sales.

​Management noted that the Centers for Medicare & Medicaid Services has assigned a J-code J3404 to the therapy effectual April 1, 2026. As a result, the institution expects fiscal Q1 2026 gross for the cause to transcend $18 million.

​Precigen, Inc. (NASDAQ:PGEN) is simply a biopharmaceutical institution focused connected processing next-generation cistron and compartment therapies, specifically successful immuno-oncology, autoimmune disorders, and infectious diseases.

While we admit the imaginable of PGEN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Hot Growth Stocks to Invest successful Right Now and 7 Ridiculously Cheap Stocks to Buy According to Wall Street Analysts. 

Disclosure: None. Follow Insider Monkey connected Google News.